Loading...
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH
Black patients are underrepresented in trials leading to FDA approval of cancer medications, according to a brief research report in the Annals of Internal Medicine.
Using FDA data, researchers identified nearly 62,000 patients who were enrolled in clinical trials between 2014 and 2018 that led to approval of cancer drugs. Black patients made up roughly 7% of enrollees.
Taking into account the proportion of cancer patients who are Black, the researchers found that Black patients were substantially underrepresented in trials of drugs for all cancer types combined — as well as those for breast, prostate, lung, and hematologic cancers; leukemia; and multiple myeloma.
The researchers write, "We believe that this discrepancy results in failed opportunities to understand cancer biology and the pharmacology of cancer medications. For example, a recent study identified increased activation of the 'unfolded protein response' in African American patients with breast cancer compared with white patients, which may correlate with an increased prevalence of tamoxifen resistance in African American patients." They call for additional research into these enrollment disparities, including the "consequences ... and how to address those consequences."
Comment
LINK(S):
Annals of Internal Medicine brief research report (Subscription required)
Background: NEJM Journal Watch Gastroenterology coverage of racial disparities in colorectal cancer survival (Your NEJM Journal Watch registration required)
NEJM Race and Medicine page (Free)